Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998

International Archives of Allergy and Immunology

Volumn 120, Issue 1, 1999, Pages 1-7

  Valent, Peter ^d   Escribano, Luis ^a   Parwaresch, Reza M ^e   Schemmel, Verena ^b   Schwartz, Lawrence B ^c   Sotlar, Karl ^e   Sperr, Wolfgang R ^e   Horny, Hans Peter ^e  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e NONE

Author keywords

c kit; CD2; Mastocytosis; Point mutations; Tryptase

Indexed keywords

CD2 ANTIGEN; STEM CELL FACTOR RECEPTOR; TRYPTASE;

AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; CELL GROWTH; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DISEASE COURSE; FAMILY HISTORY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; MASTOCYTOSIS; MYELOID LEUKEMIA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SKIN DISEASE; SYSTEMIC DISEASE;

ADULT; ANTIGENS, CD; BONE MARROW CELLS; CHYMASES; HUMANS; IMMUNOHISTOCHEMISTRY; MAST CELLS; MASTOCYTOSIS; PHENOTYPE; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SERINE ENDOPEPTIDASES; TERMINOLOGY; TRYPTASES;

EID: 0032846837     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024214     Document Type: Review

References (67)

1. Nettleship E, Tay W: Rare forms of urticaria. Br Med J 1869;ii:323-330.
2. Ellis JM: Urticaria pigmentosa. A report of a case with autopsy. AMA Arch Pathol 1949;48: 426-429.
3. Lennert K, Parwaresch MR: Mast cells and mast cell neoplasia: A review. Histopathology 1979;3:349-365.
4. Horny H-P, Parwaresch MR, Lennert K: Klinisches Bild und Prognose generalisierter Mastozytosen. Klin Wochenschr 1983;61:785-793.
5. Parwaresch MR, Horny H-P, Bödewadt-Radzun S: Mast cell disease; in Knowles DM (ed): Neoplastic Hematopathology. New York, William & Wilkins, 1992, pp 1485-1515.
6. Parwaresch MR, Horny H-P, Lennert K: Tissue mast cells in health and disease. Pathol Res Pract 1985;179:439-461.
7. Horan RF, Austen KF: Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96:5S-13S.
8. Metcalfe DD: Classification and diagnosis of mastocytosis: Current status. J Invest Dermatol 1991;96:2S-4S.
9. Horny H-P, Kaiserling E, Parwaresch MR, Lennert K: Lymph node findings in generalized mastocytosis. Histopathology 1992;21: 439-446.
10. Horny H-P, Parwaresch MR, Lennert K: Bone marrow findings in systemic mastocytosis. HumPathol 1985;16:808-814.
11. Horny H-P, Kaiserling E: Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: A histological and immunohistological study. Br J Hematol 1988; 69:449-455.
12. Prokocimer M, Polliack A: Increased bone marrow mast cells in preleukemic syndromes, acute myeloid leukemias and lympho-proliferative disorders. Am J Clin Pathol 1980;75:34-38.
13. Wimazal F, Walchshofer S, Baghestanian M, Chott A, Sperr WR, Kopp C, Sillaber C, Semper H, Horny H-P, Tröndle U, Födinger M, Schwarzinger I, Lechner K, Valent P: Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis. Wien Klin Wochenschr 1998;110:79-88.
14. Valent P, Spanblöchl E, Bankl HC, Sperr WR, Marosi Ch, Pirc-Danoewinata H, Virgolini I, Eichler H-G, Agis H, Sillaber C, Bettelheim P, Lechner K: Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemia blast crisis. Blood 1994;84:4322-4332.
15. Wimazal F, Sperr WR, Horny H-P, Carroll V, Binder BR, Fonatsch C, Walchshofer S, Födinger M, Schwarzinger I, Samorapoompichit P, Chott A, Dvorak AM, Lechner K, Valent P: Hyperfibrinolysis in a case of myelodys-plastic syndrome with leukemic spread of mast cells. Am J Hematol 1999;61:66-76.
16. Valent P, Bettelheim P: Cell surface structures on human basophils and mast cells: Biochemical and functional characterization. Adv Immunol 1992;52:333-421.
17. - cell population. Blood 1994;84:2489-2496.
18. -, colony forming cell. J Immunol; 1993;151:4221-4227.
19. Agis H, Füreder W, Bankl HC, Kundi M, Sperr WR, Willheim M, Boltz-Nitulescu G, Butterfield JH, Kishi K, Lechner K, Valent P: Comparative phenotypic analysis of human mast cells, blood monocytes and blood basophils: Dissection of three distinct lineages. Immunology 1996;87:535-543.
20. Horny H-P, Ruck M, Wehrmann M, Kaiserling E: Blood findings in generalized mastocytosis: Evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990;76:186-193.
21. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG: Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965-972.
22. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR: Hematologic manifestation of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991;91:612-624.
23. Travis WD, Li CY, Hogaland HC, Travis LB, Banks PM: Mast cell leukemia: Report of a case and review of the literature. Mayo Clin Proc 1986;61:957-966.
24. Kröber SM, Horny H-P, Ruck P, Krammerer U, Geiselhart A, Handgretinger R, Griesser H, Menke DM, Kaiserling E: Mastocytosis: Reactive or neoplastic? J Clin Pathol 1997;50:525-527.
25. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 1993;92:1736-1744.
26. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
27. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-314.
28. Worobec AS, Semere T, Nagata H, Metcalfe DD: Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998;83:2120-2129.
29. Sperr WR, Walchshofer S, Horny H-P, Födinger M, Simonitsch I, Fritsche-Polanz R, Schwarzinger I, Tschachler E, Sillaber C, Hagen W, Geissler K, Chott A, Lechner K, Valent P: Systemic mastocytosis associated with acute myeloid leukemia: Report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998;103:740-749.
30. Pignon JM, Giraudier S, Duquesnoy P, Jounault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M: A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374-376.
31. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J: Identification of activating c-kit mutations in adult-, but not childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behaviour. J Invest Dermatol 1998;111:1227-1231.
32. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu S-Z, Heiljan D, Ma Y: Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96:1609-1614.
33. Afonja O, Amorosi E, Ashman L, Takeshita K: Multilineage involvement and erythropoietin 'independent' erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 1998;77:183-186.
34. Akin C, Kirshenbaum A, Scott LM, Semere T, Metcalfe DD: Demonstration of an activating c-kit mutation in myeloid and lymphoid cells in peripheral blood and bone marrow in mastocytosis. Blood 1998;92(suppl):210a.
35. Baghestanian M, Bankl HC, Sillaber C, Beil WJ, Radaszkiewicz Th, Füreder W, Preiser J, Veselly M, Schernthaner G, Lechner K, Valent P: A case of malignant mastocytosis with circulating mast cell precursors: Biologic and phenotypic characterization of the malignant clone. Leukemia 1996;10:159-166.
36. Li WV, Kapadia SB, Sonmez-Alpan E, Steven MS, Swerdlow SH: Immuno-histochemical characterization of mast cell disease in paraffin sections using tryptase. CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996;9:982-988.
37. Horny H-P, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P: Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22: 1132-1140.
38. Fukuda T, Kamishima T, Tsuura Y, Suzuki T, Kakihara T, Naito M, Kishi K, Matsumoto K, Shibata A, Seito T: Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia. J Pathol 1995;177:139-146.
39. Agis H, Beil WJ, Bankl HC, Füreder W, Sperr WR, Ghannadan M, Baghestanian M, Sillaber C, Bettelheim P, Lechner K, Valent P: Basophil-versus mast cell lineage involvement in myelodysplastic and leukemic disorders. Leukem Lymphoma 1996;22:187-204.
40. Horny H-P, Ruck P, Xiao J-C, Kaiserling E: Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1. Hum Pathol 1993;24:355-358.
41. Valent P: Mast cell differentiation antigens: Expression in normal and malignant cells and use for diagnostic purposes. Eur J Clin Invest 1995;25:715-720.
42. Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J, Navarro JL, San Miguel JF: Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996;149:1493-1499.
43. Escribano L, Orfao A, Villarrubia J, Diaz Agustin B, Cerveró C, Rios A, Velasco JL, Ciudad J, Navarro JL, San Miguel JF: Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathologic bone marrow samples. Anal Cell Pathol 1998;16:151-159.
44. Escribano L, Orfao A, Villarrubia J, Cerveró C, Velasco JL, Martin F, San Miguel JF, Navarro JL. Expression of lymphoid-assodated antigens in mast cells: Report of a case of systemic mast cell disease. Br J Haematol 1995;91:941-943.
45. Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cerveró C, López A, Garcia Marcos MA, Bellas C, Fernández-Canadas S, Cuevas M, Sánchez A, Velasco JL, Navarro JL, San Miguel JF: Indolent systemic mast cell disease in adults: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-2736.
46. Escribano L, Orfao A, Villarrubia J, Martin F, Madruga JI, Cuevas M, Velasco JL, Rios A, San Miguel JF: Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997l;30:98-102.
47. Dalton R, Chan L, Batten E, Eridani S: Mast cell leukemia: Evidence for bone marrow origin of the pathological clone. Br J Haematol 1986;64:397-406.
48. Diaz Agustin B, Escribano L, Bravo P, Herrero S, Nunez R, Navalon R, Torrelo A, Cantalapiedra A, del Castillo LVJ, Navarro JL, San Miguel JF, Orfao A: The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br J Haematol, in press.
49. Cervero C, Escribano L, San-Miguel JF, Diaz-Augustin B, Bravo P, Villarrubia J, Garcia-Sanz R, Velasco JL, Herrera P, Vargas M, Gonzales M, Navarro JL, Orfao A: Expression of bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 1999;60:191-195.
50. Schwartz LB: The mast cell; in Kaplan AP (ed): Allergy. New York, Churchill Livingston, 1985, vol 1, pp 53-92.
51. Irani AM, Schechter NM, Craig SS, Deblois G, Schwartz LB: Two human mast cell subsets with distinct neutral protease compositions. Proc Natl Acad Sci USA 1986;83:4064-4069.
52. Castells MC, Irani AM, Schwartz LB: Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987;138:2184-2189.
53. Miller JS, Westin EH, Schwartz LB: Cloning and characterization of complementary DNA for human tryptase. J Clin Invest 1989;84: 1188-1195.
54. Miller JS, Moxley G, Schwartz LB: Cloning and characterization of a second complementary DNA for human tryptase. J Clin Invest 1990;86:864-870.
55. Vanderslice P, Ballinger SM, Tam EK, Goldstein SM, Craik CS, Caughey GH: Human mast cell tryptase: Multiple cDNAs and genes reveal a multigene serin protease family. Proc Natl Acad Sci USA 1990;87:3811-3815.
56. Pallaoro M, Fejzo MS, Shayesteh L, Blount JL, Caughey GH: Characterization of genes coding known and novel human mast cell tryptases on chromosome 16p13.3. J Biol Chem 1999;274:3355-3362.
57. Sakai K, Ren S, Schwartz LB: A novel heparin-dependent processing pathway for human tryptase: Autocatalysis followed by activation with dipeptidyl peptidase I. J Clin Invest 1996l97:988-995.
58. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96:2702-2710.
59. Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK, Van der Linden P-WG: Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis. J Clin Immunol 1994;14: 190-204.
60. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316: 1622-1626.
61. van der Linden P-WG, Hack CE, Poortman J, Vivie-Kipp YC, Struyvenberg A, van der Zwan JK: Insect-sting challenge in 138 patients: Relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol 1992;90:110-118.
62. Caplan RM: The natural course of urticaria pigmentosa. Arch Dermatol 1963;87:146-157.
63. Metcalfe DD: The treatment of mastocytosis: An overview. J Invest Dermatol 1991;96:55S-59S.
64. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R: Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-623.
65. Parker RI: Hematologic aspects of mastocytosis. II. Management of hematologic disorders in association with systemic mast cell disease. J Invest Dermatol 1991;96:52S-53S.
66. Valent P: Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996;108:385-397.
67. Horny H-P, Parwaresch MR, Kaiserling E, Müller K, Olbermann M, Mainzer K, Lennert K: Mast cell sarcoma of the larynx. J Clin Pathol 1986;39:596-602.